Jeremy Flint

Jeremy Flint

InvestorPlace Contributor

Expertise: Fixed-income investing, macroeconomic news; oil, gas, and utilities industries

Education: BS, Political Science & International Affairs, Florida State University. MBA, Finance, University of California - Davis

Jeremy Flint is an MBA graduate and freelance finance writer primarily emphasizing content creation for wealth managers and investment funds. A former U.S. Army officer, he brings strategic vision to content development and tactical analysis to stock picking and economic assessments.

He’s been obsessed with the markets since he was a teenager and is passionate about spreading financial literacy by using his expertise to break down obscure market concepts for retail traders. His main focus areas are fixed-income investing, alternative investments, macroeconomic news, and the oil, gas, and utilities sectors.

Jeremy lives in Austin, TX with his wife and son. His work can also be found at www.jeremyflint.work or on his LinkedIn.

Recent Articles

3 Investments Warren Buffett Is Making That You Should Too

By Jeremy Flint, InvestorPlace Contributor

Warren Buffett holds his position in these three stocks amid industry-specific risks, rising interest rates and inflation.

The Top 3 Cannabis Stocks by Market Cap: Buy, Sell or Hold?

By Jeremy Flint, InvestorPlace Contributor

Cannabis stocks are well off past highs, but these three remain in the right with the highest market caps in the industry. Which is best?

The 3 Most Reliable Dividend Stocks to Buy for August 2023

By Jeremy Flint, InvestorPlace Contributor

As equities remain volatile this month, fixed-income investments are gaining attention. Here are three of the most reliable dividend stocks.

7 Blue-Chip Stocks to Buy at an All-Time Low in August

By Jeremy Flint, InvestorPlace Contributor

August started with a whimper, as the recent stock rally receded. After hitting an end-of-July $457 high, the SPDR S&P 500 ETF (NYSEARCA:SPY) pared back…

The 3 Best Biotech Stocks to Buy in August

By Jeremy Flint, InvestorPlace Contributor

Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news.

Load More